Does TISLELIZUMAB Cause Malignant neoplasm progression? 11 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 11 reports of Malignant neoplasm progression have been filed in association with TISLELIZUMAB (TEVIMBRA). This represents 0.2% of all adverse event reports for TISLELIZUMAB.
11
Reports of Malignant neoplasm progression with TISLELIZUMAB
0.2%
of all TISLELIZUMAB reports
2
Deaths
2
Hospitalizations
How Dangerous Is Malignant neoplasm progression From TISLELIZUMAB?
Of the 11 reports, 2 (18.2%) resulted in death, 2 (18.2%) required hospitalization.
Is Malignant neoplasm progression Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for TISLELIZUMAB. However, 11 reports have been filed with the FAERS database.
What Other Side Effects Does TISLELIZUMAB Cause?
Myelosuppression (2,142)
White blood cell count decreased (327)
Neutrophil count decreased (277)
Hepatic function abnormal (221)
Pruritus (213)
Rash (208)
Platelet count decreased (183)
Pyrexia (175)
Nausea (165)
Diarrhoea (145)
What Other Drugs Cause Malignant neoplasm progression?
PEMBROLIZUMAB (10,111)
NIVOLUMAB (9,363)
ENZALUTAMIDE (4,696)
CARBOPLATIN (4,177)
EVEROLIMUS (3,789)
PACLITAXEL (3,484)
LETROZOLE (3,445)
IPILIMUMAB (3,296)
FULVESTRANT (3,221)
LENVATINIB (2,929)
Which TISLELIZUMAB Alternatives Have Lower Malignant neoplasm progression Risk?
TISLELIZUMAB vs TISOTUMAB VEDOTIN
TISLELIZUMAB vs TISOTUMAB VEDOTIN-TFTV
TISLELIZUMAB vs TITANIUM DIOXIDE\ZINC
TISLELIZUMAB vs TIVICAY
TISLELIZUMAB vs TIVOZANIB